Effects of liraglutide versus sitagliptin on circulating cardiovascular biomarkers, including circulating progenitor cells, in individuals with type 2 diabetes and obesity: Analyses from the LYDIA trial

A randomised, open label, active comparator trial assessing the effects of 26 weeks of liraglutide or sitagliptin on cardiovascular function in young obese adults with type 2 diabetes

(2020) David R. Webb et al.   DIABETES OBESITY & METABOLISM

GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials

(2020) Matthew P. Gilbert et al.   Frontiers in Endocrinology

Adults with early-onset type 2 diabetes (aged 18–39 years) are severely underrepresented in diabetes clinical research trials

(2020) Jack A. Sargeant et al.   DIABETOLOGIA

Effect of Saxagliptin on Endothelial Function in Patients with Type 2 Diabetes: A Prospective Multicenter Study

(2019) Masato Kajikawa et al.   Scientific Reports

Liraglutide Increases VEGF Expression via CNPY2-PERK Pathway Induced by Hypoxia/Reoxygenation Injury

(2019) Chong Liu et al.   Frontiers in Pharmacology

GLP‐1 receptor agonists for prevention of cardiorenal outcomes in type 2 diabetes: An updated meta‐analysis including the REWIND and PIONEER 6 trials

(2019) Dario Giugliano et al.   DIABETES OBESITY & METABOLISM

Effects of Sitagliptin on the Coronary Flow Reserve, Circulating Endothelial Progenitor Cells and Stromal Cell-derived Factor-1alpha

(2019) Tetsuji Morishita et al.   INTERNAL MEDICINE

A review of dipeptidyl peptidase-4 inhibitors. Hot topics from randomized controlled trials

(2018) Carolyn F. Deacon   DIABETES OBESITY & METABOLISM

A review of the anti-inflammatory properties of antidiabetic agents providing protective effects against vascular complications in diabetes

(2018) Habib Yaribeygi et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Glucagon-like peptide-1 analogue liraglutide ameliorates atherogenesis via inhibiting advanced glycation end product-induced receptor for advanced glycosylation end product expression in apolipoprotein-E deficient mice

(2017) Peicheng Li et al.   Molecular Medicine Reports

Levels of Circulating Progenitor Cells, Cardiovascular Outcomes and DeathNovelty and Significance

(2016) Mauro Rigato et al.   CIRCULATION RESEARCH

Acute Effects of Linagliptin on Progenitor Cells, Monocyte Phenotypes, and Soluble Mediators in Type 2 Diabetes

(2016) Gian Paolo Fadini et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

The Oral Dipeptidyl Peptidase-4 Inhibitor Sitagliptin Increases Circulating Endothelial Progenitor Cells in Patients With Type 2 Diabetes: Possible role of stromal-derived factor-1 

(2010) G. P. Fadini et al.   DIABETES CARE